BSE
MARKET ANALYSIS NEWS CORPORATE INFORMATION CORPORATE ACTIONS OTHER MARKETS
Your Result on : Company News Details
Marksans Pharma Ltd Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
524404
ISIN Demat
INE750C01026
Book Value (Rs)
36.4615746
NSE Symbol
MARKSANS
Divident Yield %
0.35
Market Cap
(Rs In Cr.)
11,606
P/E (TTM)
38.57
EPS (TTM)
6.64
Face Value
(Rs)
1
Back
Marksans Pharma consolidated net profit rises 63.59% in the March 2026 quarter
26-May-26   Hrs IST

Net profit of Marksans Pharma rose 63.59% to Rs 148.13 crore in the quarter ended March 2026 as against Rs 90.55 crore during the previous quarter ended March 2025. Sales rose 20.84% to Rs 856.11 crore in the quarter ended March 2026 as against Rs 708.46 crore during the previous quarter ended March 2025.

For the full year,net profit rose 9.81% to Rs 417.90 crore in the year ended March 2026 as against Rs 380.58 crore during the previous year ended March 2025. Sales rose 12.51% to Rs 2950.94 crore in the year ended March 2026 as against Rs 2622.85 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales856.11708.46 21 2950.942622.85 13
OPM %22.8317.92 -20.3620.31 -
PBDT224.29138.84 62 659.19587.35 12
PBT200.00116.09 72 560.56503.97 11
NP148.1390.55 64 417.90380.58 10

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)